Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMF29Q5)

Drug Name
Connexyn Drug Info
Synonyms
Estulic; Intuniv; Tenex; GUANFACINE HCL; Guanfacine hydrochloride; G 1043; LON 798; BS 100-141; Guanfacine hydrochloride [USAN:JAN]; SPD-503; Tenex (TN); BS-100-141; Guanfacine hydrochloride (JAN/USP); N-(Aminoiminomethyl)-2,6-dichlorobenzeneacetamide hydrochloride; N-(Aminoiminomethyl)-2,6-dichlorophenylacetamide monohydrochloride; N-(aminoiminomethyl)-2,6-dichloro-benzeneacetamide hydrochloride; N-Amidino-2-(2,6-dichlorophenyl)acetamide hydrochloride; N-Amidino-2-(2,6-dichlorophenyl)acetamide monohydrochloride; N-carbamimidoyl-2-(2,6-dichlorphenyl)acetamidhydrochlorid; N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide hydrochloride; Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-, monohydrochloride; Benzeneacetamide, N-(aminoiminomethyl)-2,6-dichloro-, hydrochloride (1:1)
Indication
Disease Entry ICD 11 Status REF
Attention deficit hyperactivity disorder 6A05.Z Approved [1]
Cross-matching ID
PubChem CID
71401
ChEBI ID
CHEBI:5559
CAS Number
CAS 29110-48-3
TTD Drug ID
DMF29Q5
INTEDE Drug ID
DR0796

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Adrenergic receptor alpha-2A (ADRA2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lofexidine DM1WXA6 Heroin and opiate withdrawal 6C43 Approved [6]
MOXONIDINE DMGFB0E Alcohol dependence 6C40.2 Approved [7]
Guanfacine DMPN5IH Attention deficit hyperactivity disorder 6A05.Z Phase 4 [8]
A295 DM55GO2 Aggressive cancer 2A00-2F9Z IND submitted [9]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [10]
DSP-1200 DM4WSHG Depression 6A70-6A7Z Phase 1 [11]
MAZAPERTINE DMRHYAU N. A. N. A. Discontinued in Phase 2 [12]
NMI-870 DMU596F Sexual dysfunction HA00-HA01 Discontinued in Phase 2 [13]
SNAP-5089 DMROJEN Heart arrhythmia BC65 Terminated [14]
A-80426 DMBC3DG N. A. N. A. Terminated [15]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [16]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [17]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [18]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [19]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [20]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [21]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [22]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [23]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [17]
Verapamil DMA7PEW Angina pectoris BA40 Approved [24]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Renin (REN)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ranitidine DM0GUSX Gastric ulcer DA60 Approved [25]
Acebutolol DM0TI4U Hypertension BA00-BA04 Approved [26]
Nitrendipine DM21C09 Hypertension BA00-BA04 Approved [27]
Reboxetine DM26PRD Depression 6A70-6A7Z Approved [28]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [29]
Ramipril DM2R68E Acute heart failure BD10-BD13 Approved [30]
Rhucin DM3ADGP Erectile dysfunction HA01.1 Approved [31]
Naloxone DM3FXMA Narcotic depression 6A7Z Approved [32]
Epinephrine DM3KJBC Acute asthma CA23 Approved [33]
Chlorthalidone DM4DMBT Edema MG29 Approved [34]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Somatotropin (GH1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Polyethylene glycol DM4I1JP Constipation DD91.1 Approved [35]
Clonidine DM6RZ9Q Attention deficit hyperactivity disorder 6A05.Z Approved [36]
Adenosine triphosphate DM79F6G Malnutrition 5B50-5B71 Approved [37]
Cyproheptadine DM92AH3 Allergic rhinitis CA08.0 Approved [38]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [39]
Sodium oxybate DMBOV5P Narcolepsy 7A20 Approved [40]
Ethanol DMDRQZU Chronic pain MG30 Approved [35]
Gamma Hydroxybutyric Acid DMGBKVD Narcolepsy 7A20 Approved [41]
Hydrocortisone DMGEMB7 Acne vulgaris ED80 Approved [42]
Octreotide DMHIDCJ Acromegaly 5A60.0 Approved [43]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adrenergic receptor alpha-2A (ADRA2A) TTWG9A4 ADA2A_HUMAN Agonist [2]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) Main DME DE4LYSA CP3A4_HUMAN Substrate [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Renin (REN) OT52GZR2 RENI_HUMAN Gene/Protein Processing [4]
Somatotropin (GH1) OT92RTRD SOMA_HUMAN Gene/Protein Processing [5]

References

1 Shire Announces NDA Submission of Guanfacine Extended Release for the Treatment of ADHD in Children and Adolescents, 2009. FDA Approved - September 2, 2009
2 alpha2A-adrenergic receptors heterosynaptically regulate glutamatergic transmission in the bed nucleus of the stria terminalis. Neuroscience. 2009 Sep 29;163(1):339-51.
3 Microsomal catalyzed N-hydroxylation of guanfacine and reduction of N-hydroxyguanfacine. Arch Pharm (Weinheim). 1997 Oct;330(9-10):303-6.
4 [Effect of 5-month guanfacine treatment on the renin-angiotensin-aldosterone system and some metabolic factors in patients with diabetes mellitus type II and hypertension]. Pol Tyg Lek. 1992 Nov 16-30;47(46-48):1045-7.
5 Effect of centrally acting alpha-adrenergic agonists on sympathetic nervous system function in humans. Hypertension. 1984 Sep-Oct;6(5 Pt 2):II57-62. doi: 10.1161/01.hyp.6.5_pt_2.ii57.
6 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
7 Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5.
8 Scientific rationale for the use of alpha2A-adrenoceptor agonists in treating neuroinflammatory cognitive disorders. Mol Psychiatry. 2023 Apr 7:1-13.
9 Clinical pipeline report, company report or official report of Klus Pharma
10 A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
11 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
12 A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
13 Female Sexual Dysfunction: Therapeutic Options and Experimental Challenges. Cardiovasc Hematol Agents Med Chem. 2009 October; 7(4): 260-269.
14 Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8.
15 Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71.
16 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
17 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
18 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
19 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
20 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
21 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
22 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
23 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
24 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
25 Effects of histamine H2-receptor blockade on the cardiovascular reflex response to lower-body negative pressure in man. Acta Physiol Scand. 1990 May;139(1):161-72. doi: 10.1111/j.1748-1716.1990.tb08909.x.
26 Addition of acebutolol to diuretics in hypertension. Clin Pharmacol Ther. 1981 Dec;30(6):739-44. doi: 10.1038/clpt.1981.232.
27 Relative potency of a beta-blocking and a calcium entry blocking agent as antihypertensive drugs in black patients. Eur J Clin Pharmacol. 1986;29(5):523-7. doi: 10.1007/BF00635887.
28 Influences of norepinephrine transporter function on the distribution of sympathetic activity in humans. Hypertension. 2006 Jul;48(1):120-6. doi: 10.1161/01.HYP.0000225424.13138.5d. Epub 2006 May 22.
29 Effects of sulindac and naproxen on prostaglandin excretion in patients with impaired renal function and rheumatoid arthritis. Am J Med. 1990 Sep;89(3):313-21. doi: 10.1016/0002-9343(90)90344-d.
30 Effects of an angiotensin converting enzyme inhibitor, ramipril, on intracranial circulation in healthy volunteers. off. Br J Clin Pharmacol. 1992 Sep;34(3):224-30. doi: 10.1111/j.1365-2125.1992.tb04128.x.
31 Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites. Am J Physiol Renal Physiol. 2005 May;288(5):F1044-52. doi: 10.1152/ajprenal.00142.2004. Epub 2004 Dec 21.
32 beta-Endorphin and essential hypertension: importance of the clonidine-naloxone interaction. Acta Physiol Hung. 1985;65(2):217-26.
33 Hypokalemia from beta2-receptor stimulation by circulating epinephrine. N Engl J Med. 1983 Dec 8;309(23):1414-9. doi: 10.1056/NEJM198312083092303.
34 Detection of low-renin hypertension; evaluation of out-patient renin-stimulating methods. Clin Sci Mol Med. 1975 Feb;48(2):91-6. doi: 10.1042/cs0480091.
35 Metal-catalyzed oxidation of human growth hormone: modulation by solvent-induced changes of protein conformation. J Pharm Sci. 2001 Jan;90(1):58-69. doi: 10.1002/1520-6017(200101)90:1<58::aid-jps7>3.0.co;2-w.
36 Assessment of MK-912, an alpha 2-adrenoceptor antagonist, with use of intravenous clonidine. Clin Pharmacol Ther. 1989 Jul;46(1):103-9. doi: 10.1038/clpt.1989.113.
37 Phosphatidylinositol 4-OH kinase is a downstream target of neuronal calcium sensor-1 in enhancing exocytosis in neuroendocrine cells. J Biol Chem. 2003 Feb 21;278(8):6075-84. doi: 10.1074/jbc.M204702200. Epub 2002 Dec 5.
38 [Toxicity of cyproheptadine. Side effects and accidental overdosage (author's transl)]. Monatsschr Kinderheilkd (1902). 1978 Mar;126(3):123-6.
39 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
40 Failure of gammahydroxy butyric acid to stimulate growth hormone secretion in cocaine addicts. Neuropeptides. 1997 Oct;31(5):459-62. doi: 10.1016/s0143-4179(97)90040-8.
41 Thyrotropin-releasing hormone-induced GH release after cocaine withdrawal in cocaine addicts. Neuropeptides. 1999 Dec;33(6):522-5. doi: 10.1054/npep.1999.0773.
42 Effects of cortisol and cocaine on plasma prolactin and growth hormone levels in cocaine-dependent volunteers. Addict Behav. 2005 May;30(4):859-64. doi: 10.1016/j.addbeh.2004.08.019.
43 Effect of a somatostatin analogue, octreotide, on renal haemodynamics and albuminuria in acromegalic patients. Eur J Clin Invest. 1992 Jul;22(7):494-502. doi: 10.1111/j.1365-2362.1992.tb01496.x.